Formycon AG Asset Resilience Ratio
Formycon AG asset resilience ratio. Formycon AG (FYB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Formycon AG fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Formycon AG (2010–2025)
Asset resilience ratio of Formycon AG from 2010 to 2025. This chart shows how Formycon AG's Asset Resilience Ratio has changed over time. Read Formycon AG debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Formycon AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see FYB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00K | 0.0% |
| Total Liquid Assets | €1.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Formycon AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Formycon AG Industry Peers by Asset Resilience Ratio
Compare Formycon AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Formycon AG Asset Resilience Ratio by Year (2010–2025)
Formycon AG asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Formycon AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €1.00K ≈ $1.17K |
€739.53 Million ≈ $864.58 Million |
-5.42pp |
| 2024-12-31 | 5.42% | €41.84 Million ≈ $48.92 Million |
€771.72 Million ≈ $902.22 Million |
+2.38pp |
| 2023-12-31 | 3.04% | €27.04 Million ≈ $31.61 Million |
€890.36 Million ≈ $1.04 Billion |
-17.39pp |
| 2022-12-31 | 20.42% | €174.35 Million ≈ $203.83 Million |
€853.70 Million ≈ $998.06 Million |
-15.18pp |
| 2021-12-31 | 35.61% | €25.18 Million ≈ $29.44 Million |
€70.72 Million ≈ $82.67 Million |
-20.28pp |
| 2020-12-31 | 55.88% | €42.25 Million ≈ $49.39 Million |
€75.60 Million ≈ $88.38 Million |
+14.14pp |
| 2019-12-31 | 41.74% | €22.35 Million ≈ $26.13 Million |
€53.56 Million ≈ $62.61 Million |
+10.68pp |
| 2018-12-31 | 31.06% | €12.31 Million ≈ $14.39 Million |
€39.62 Million ≈ $46.32 Million |
-19.15pp |
| 2017-12-31 | 50.21% | €15.48 Million ≈ $18.10 Million |
€30.83 Million ≈ $36.04 Million |
-3.83pp |
| 2016-12-31 | 54.04% | €13.61 Million ≈ $15.91 Million |
€25.19 Million ≈ $29.45 Million |
-18.43pp |
| 2015-12-31 | 72.47% | €19.67 Million ≈ $23.00 Million |
€27.15 Million ≈ $31.74 Million |
+19.62pp |
| 2014-12-31 | 52.85% | €8.93 Million ≈ $10.45 Million |
€16.91 Million ≈ $19.77 Million |
-8.70pp |
| 2013-12-31 | 61.55% | €9.51 Million ≈ $11.11 Million |
€15.44 Million ≈ $18.06 Million |
+61.53pp |
| 2012-12-31 | 0.02% | €1.84K ≈ $2.15K |
€7.64 Million ≈ $8.93 Million |
-32.15pp |
| 2011-12-31 | 32.18% | €1.80 Million ≈ $2.10 Million |
€5.59 Million ≈ $6.54 Million |
-26.24pp |
| 2010-12-31 | 58.42% | €2.50 Million ≈ $2.92 Million |
€4.28 Million ≈ $5.00 Million |
-- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more